Compositions, kits and methods for administration of antilipemic

Details Compositions, kits and methods for administration of antilipemic Compositions, kits and methods for administration of antilipemic

1997-09-26

1999-11-09

MacMillan, Keith D.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

514404, 514405, 514420, 514568, 514569, 514570, 514823, A61K 31715, A61K 3133

Patent

active

059815558

ABSTRACT:
The present invention concerns composition, kits and methods for reducing the flushing effect (cutaneous erythema) of an antilipemic drug, for treating hyperlipemia, for improving the effectiveness of an anti-platelet aggregating drug (e.g., in nonresponders) and for treating thrombosis. The present compositions and kits for reducing the flushing effect and for treating hyperlipemia contain an antilipemic drug (such as niacin) and either a sustained release NSAID (such as aspirin) or an NSAID and a carboxylic acid compound other than the NSAID and antilipemic drug. The kits contain (a) pre-dosages of the NSAID and optional carboxylic acid compound and (b) an antilipemic dosage of the antilipemic drug, which optionally may be combined with NSAID and optional carboxylic acid compound in an amount effective to maintain the reduction of the flushing effect. The present method of treating hyperlipemia comprises predosing the patient with a sustained release NSAID or an NSAID and a carboxylic acid compound other than the NSAID and antilipemic drug at least 2 hours before administering the antilipemic drug. The present compositions and kits for increasing the effectiveness of an anti-platelet aggregating drug contain an NSAID such as aspirin, niacin or a congener thereof, and optionally, a carboxylic acid other than the NSAID, such as citric acid.

REFERENCES:
patent: 4965252 (1990-10-01), Kuhrts
patent: 5023245 (1991-06-01), Kuhrts
patent: 5041430 (1991-08-01), Addicks et al.
patent: 5292534 (1994-03-01), Valentine et al.
patent: 5401730 (1995-03-01), Sauvage et al.
Medline Abstract #85225813, Hamazaki et al, Apr. 1985.
Medline Abstract #82137645, Wilkin et al, Apr. 1982.
Medline Abstract #77263172, Anderson et al, Jul. 1977.
Andersson, et al., Acta pharmacol. et toxicol. 41:1-10 (1997).
Ding et al, Am. Coll. Clin Pharm., Abstract.
Ding et al, 2nd Cardio. Pharm. Int'l. Symp., Abstract 6.
Ding et al, "Dose-Dependent Nicotinic Acid Induced Flush", Abstract 7a.
Ding et al, "Does Aspirin Block the Nicotinic Acid Induced Flush?", Abstract 7.
Ding et al, Clin. Pharmacol. Ther., 46(6):642-647 (1989).
Hamazaki et al, Elsevier Scientific Publishers Ireland, Ltd. (1985).
Helgason et al, Stroke, 25:2331-2336 (1994).
Kaijser et al, Medical Biology, 57:114-117, 1979.
King et al, Americal J. of Medicine, 97:323-331, Oct. 1994.
Kreisberg et al, American J. of Medicine, 97:313-316, Oct. 1994.
Lasagna. JAMA, 271(9):709-710, 1994.
McKenney et al, JAMA, 271(9) 672-677, 1994.
Morrowet al, J. of Investig. Dermatology, 98:812-815, 1992.
Morrow et al, Prostaglandins, 38(2):263-274, 1989.
Stern et al, Clin Pharmacol Ther, 50(1):66-70, 1991.
Svedmyr et al, Acta pharmacol. et toxicol, 41:397-400, 1977.
Whelan et al, J. Fam. Prac., 34(2):165-168, 1992.
Wilkin et al, Clin. Pharmacol. Ther., 31(4):478-482, 1982.
Wilkin et al, Clin. Pharmacol. Ther., 38(3):273-277, 1985.

Affiliated with

Also associated with

Rating

Compositions, kits and methods for administration of antilipemic does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions, kits and methods for administration of antilipemic, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions, kits and methods for administration of antilipemic will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1456470